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+781 C/TAbstract Background and aim: Previous studies have observed the association between inflamma-
tion and chronic kidney disease (CKD). The role played by Interleukin 8 (IL8) gene polymorphism
has not been studied yet. Hence, the present study has been designed as the first attempt to identify
the possible associations between polymorphism of the IL-8 gene and patients with diabetic CKD
and on continuous ambulatory peritoneal dialysis (CAPD).
Materials and methods: A total of 150 participants were selected from a private nephrology outpa-
tient clinic. The subjects were divided into three groups: healthy individuals without any renal com-
plications (group 1, control, n= 50), patients with diabetic chronic kidney disease of stages 3 and 4
(group 2, n= 50) and CAPD (group 3, n= 50). Blood deoxyribo nucleic acid (DNA) isolated from
the members of the study group, was confirmed by agarose gel electrophoresis and primers specific
for IL8 gene were designed, using primer3 software tool.
Results: Restriction digestion of the amplicons with Escherichia coli restriction enzyme I (EcoRI) ended
up in 203 base pairs (bp) band in control and 108 bp band in all diabetic and non-diabeticCKD.This indi-
cated the presence of polymorphism in+781 Cytosine/Thymine (C/T) of IL-8 gene in diabetic CKD and
CAPD patients. Statistical analysis of the distribution of frequencies of alleles C and T by chi square test
confirmed thepresenceofpolymorphismat+781C/Tof IL-8gene inpatient groups compared to control.
Conclusion: Thepolymorphism in+781C/Tof IL-8 gene studied in thiswork suggests its possible role as
an inflammatory marker for both chronic kidney disease and CAPD.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).(Ayder
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As indicated by world health organization (WHO) Worldwide
disease burden task, infections of the kidney and urinary tract
add to worldwide burden with around 850,000 passings consis-
tently and 115,010,107 inability balanced life years.1 CKD is
the twelfth driving reason for death and seventeenth reason
for disability. For quite a while, it has been assumed that about
100,000 new patients with ESRD in India require renal substi-
tution treatment consistently in view of information from ter-
tiary referral centers.2,3 The reported pervasiveness of CKD
was 0.86% in the study population and 1.39% in the control
district in Chennai when assessed amid counteractive action
program began at group level.4 The commonness of ESRD
seems, by all accounts, to be 785 for every million population
in India. Peritoneal dialysis (PD) is for some time built up as a
noteworthy choice for renal replacement therapy in patients
with end-stage renal infection or stage five of CKD. The essen-
tial intricacy of PD is infection due to the presence of a perma-
nent tube in the abdomen. Continuous ambulatory peritoneal
dialysis (CAPD) is one of the sorts of PD where the patient can
do the exchanges himself three to four times each day. Inflam-
mation contributes to the progression of CKD by inducing the
release of cytokines and the increased production and activity
of adhesion molecules, which together contribute to T cell
adhesion and migration into the interstitium, subsequently
attracting pro-fibrotic factors. Inflammation in CKD also
causes mortality from cardiovascular disease by contributing
to the development of vascular calcifications and endothelial
dysfunction.5
The inter individual variability in developing CKD might
be because of polymorphisms of various genes encoding
cytokines and other mediators of inflammation. Interleukin-8
(IL-8), a chemokine furthermore alluded to as neutrophil initi-
ating peptide-1 and monocyte-inferred neutrophil chemotactic
component, is combined as a 99-amino acid antecedent, dis-
charged after cleavage of a single sequence of 20 residues,
and handled by rehashed N-terminal cleavage yielding several
biologically active variants.6,7,41 Some IL-8 single nucleotide
polymorphisms (SNPs) including +781C/T (rs2227306) were
affirmed to be identified with the transcriptional level of IL-
88 and might be connected with the event or advancement of
an assortment of sicknesses.9–13
Past studies have noticed the relationship between inflam-
mation and CKD,14 but the relationship between these twoTable 1 Clinical parameters for study population.
Parameters Diabetic CKD
Age in years 61.37 ± 12.98
BMI 23.96 ± 3.06
Bl.Glucose (mg/dl) 180.45 ± 36.03
Bl.Urea (mg/dl) 99.6 ± 48
S.Creatinine (mg/dl) 4.60 ± 2.45
S.Sodium (meq/dl) 135.85 ± 10.98
S.Potassium (meq/dl) 3.96 ± 1.97
S.CRP (mg/dl) 6.48 ± 3.47
Total cholesterol (mg/dl) 241.63 ± 37.83
Triglycerides (mg/dl) 224.20 ± 23.19
HDL (mg/dl) 27.6 ± 5.6
LDL (mg/dl) 186.4 ± 29.12has not been studied yet in point of interest as for IL-8; how-
ever, IL-1, IL-6 and IL-10 are understood as inflammatory
markers connected with CKD.15 Subsequently, the present
case-control study was outlined as (to the best of our insight)
the main endeavor to recognize conceivable relationship
between polymorphism of the IL-8 gene and patients with
CKD and on CAPD regimen in the number of inhabitants
in Tiruchirappalli.
2. Materials and methods
2.1. Study subjects
A total of 150 participants were recruited from a private
nephrology outpatient clinic and their clinical parameters are
given in Table 1. The subjects were divided into three groups:
patients with chronic kidney disease (group 1, n = 50) with var-
ious stages according to the National Kidney Foundation clas-
sification16: Stage I (GFR> 90 ml/min/1.73 m2) normal
kidney function but urine findings or structural abnormalities
or genetic trait points to kidney disease (n= 05), stage II
(60–89 ml/min/1.73 m2) mildly reduced kidney function
(n = 10), stage III (30–59 ml/min/1.73 m2) moderately reduced
kidney function (n = 10), stage IV (15–29 ml/min/1.73 m2)
severely reduced kidney function (n= 18) and stage V
(<15 ml/min/1.73 m2) end stage kidney failure (n = 17);
patients on dialysis (CAPD) (group 2, n = 50), healthy individ-
uals without any renal complications (group 3, control,
n= 50). The clinical characteristics of study population are
given in Table 1. The following inclusion criteria were
considered for the present study: (i) 18 years of age or older,
(ii) estimated glomerular filtration rate (eGFR) between
<15–89 mL/min/1.73 m2 for CKD group, (iii) adult CAPD
patientsP18 years and at least 3 months experience on CAPD,
(iv) willing and able to comply with clinic visits and study-
related procedures and (v) provide signed informed consent
and exclusion criteria were as follows: (i) recent infection or
hospitalization (within one month), (ii) history of active or
chronic hepatitis B, history of active or chronic hepatitis C,
human immunodeficiency virus (HIV), (iii) history of tubercu-
losis (patient must be purified protein derivate negative), (iv)
patients taking tumor necrosis factor (TNF) inhibitors, TNF
blocker, interleukin-6 (IL-6) blockers or interleukin-1 (IL-1)
blocking drugs, (v) having clinically significant chronic lym-
phopenia (low white blood cell count), and (vi) history ofCAPD Control
58.2 ± 9.78 56.54 ± 11.9
21.63 ± 4.18 20.93 ± 4.73
127.83 ± 11.62 118.86 ± 11.17
91. 11 ± 53.20 22.1 ± 15.9
5.9 ± 1.29 1.32 ± 0.62
137.66 ± 9.50 139 ± 5.95
4.36 ± 1.75 4.1 ± 0.95
6.80 ± 2.83 1.06 ± 0.88
239.10 ± 27.53 192.88 ± 33.71
218.81 ± 21.67 167.04 ± 32.0
26.4 ± 4.93 34.5 ± 4.3
187.9 ± 31.50 146.72 ± 22.61
Figure 1 Genomic DNA isolation from blood of cases and
controls. Lane 1 – marker (Lambda DNA/EcoRI digest), Lane 3 –
blood genomic DNA (group I), Lane 4 – blood genomic DNA
(group II), Lane 5 – blood genomic DNA (group III).
Evaluation of Interleukin 8 gene polymorphism 217malignancy in the prior 5 years. Any history of melanoma or
lymphoma was excluded from the study. Informed consent
was obtained from all individual participants included in the
study. All procedures performed in studies involving human
participants were in accordance with the ethical standards of
the institutional and/or national research committee and with
the 1964 Helsinki declaration and its later amendments or com-
parable ethical standards. The present study protocol has been
approved by local hospital ethics committee.
2.2. Genotyping
Blood samples (5.0 ml) were drawn from the peripheral vein of
cases and controls into ethylene diamine tetra acetic acid
(EDTA) tubes by a qualified laboratory technician. Genomic
DNA extraction from the samples was performed by the stan-
dard salting out method (Medox Biotech Pvt. Ltd., Chennai,
India Catalog. No: MX-1135-02).
About 4 ll of the DNA sample was mixed with 2996 ll of
TE buffer and its absorbance was read at 260 nm by using
UV–Visible spectrophotometer. 3 mL of TE buffer served as
a blank. An optical density (OD) of one corresponds to
approximately 50 lg of double standard DNA.17 Based on
the OD value, DNA sample concentration was quantified.
Quantity ofDNAðng=llÞ¼ODat260nm50Dilution factor
1000
Primers specific for IL8 gene were designed using primer3
software tool and the details of forward primer and reverse pri-
mer 50-CTCTAACTCTTTATATAGGAATT-30 (length:
23 bp, Tm: 46 C), 50-GATTGATTTTATCAACAGGCA-30
(length: 21 bp, Tm: 47 C) respectively.
Genomic DNA isolated from blood was subjected to PCR
using the primers mentioned above followed by restriction
digestion with EcoRI. Polymerase chain reaction with restric-
tion fragment length polymorphism (PCR–RFLP) was used
to genotype selected polymorphisms within IL-8 + 781 C/T
according to protocols described by Carrero et al.18 PCR
amplification of IL 8 gene was evaluated in a 20 ll reaction
mixture containing 200 ng of the template DNA, 7.5 pmol/l
of each primer, 0.2 mM of each dNTP, 1.5 mM MgCl2,
2.5 lL10X buffer and 1 U Taq polymerase. The cycling condi-
tions for PCR were initial denaturation at 94 C for 1 min 1
cycle, followed by 30 cycles of 94 C for 1 min (melting),
58 C for 30 s (annealing), 72 C for 1 min (extension) and final
extension at 72 C for 8 min. The amplified PCR products
were analyzed on 2% agarose gel (w/v) containing ethidium
bromide. Agarose gel was visualized using gel documentation
system (BioRad, USA). Strict aseptic conditions were followed
and negative control was included. About 5 ll aliquot of prod-
ucts was loaded on 2% agarose in 1X TAE buffer and at 50 V
for 45 min. 100 bp DNA ladder was used as the marker and
the products were visualized in a UV transilluminator.
2.3. Statistical analysis
All statistical analyses were performed with SPSS software ver-
sion 14.0 for Microsoft Windows. Data were summarized as
mean ± SD, range or percentage. Allele and genotypic fre-
quency was calculated by direct gene counting method. Com-
parison of the different genotypes was done by using Chi-square test. Odds ratios were calculated with a 95% confidence
interval limit. P < 0.05 was considered statistically significant.
3. Results
Blood DNA isolated from the members of the study group was
confirmed by agarose gel electrophoresis and the size was
found to be 23 kb as compared with the Lamba DNA/Hind
III digest used as marker (Fig. 1). IL-8 polymorphism was
checked in study groups using PCR-RFLP as per prescribed
protocols. PCR amplification of blood DNA of both controls
and cases resulted in a band of length 203 bp which was con-
firmed by loading on 2% agarose gel (Fig. 2). Restriction
digestion of the amplicons with EcoRI ended up in 203 bp
band in controls but a band of 108 occurred in both CKD
and CAPD groups (Fig. 3). This indicated the presence of
polymorphism in +781 C/T of IL-8 gene in both CKD and
CAPD groups. The genotype and allele distribution of IL-8
gene polymorphisms in three groups under study are given in
Table 2. The IL 8 genotype was distributed as CT, 24 (48%),
CC, 18 (36%); TT and 8 (46%), in control group. The CAPD
patients represented CC, 13 (26%); TT, 12 (24%) and CT, 25
(50%). The CKD group has shown CC, 9 (18%); TT, 20
(40%) and CT, 21 (42%).
The genotypic (CC and TT) and allelic (C and T) frequency
distributions in the study groups were also compared and are
presented in Table 3. Significantly different CC and TT geno-
types and C and T allele distributions were observed in CKD
as compared to controls and also significant differences were
observed between Control and CAPD patients (Table 3).
Statistical analysis of the distribution of frequencies of alle-
les C and T was done by chi square test. Hence, the null
hypothesis of equal distribution of the two alleles in the study
population could be rejected with bias for T allele. This con-
firmed the presence of polymorphism at +781 C/T of IL-8
gene in cases compared to controls.
Figure 2 PCR amplification of IL-8 gene in cases and controls.
Lane 1 – marker (100 bp ladder), Lane 3 – PCR product (group I),
Lane 4 – PCR product (group II), Lane 5 – PCR product (group
III).
Figure 3 Restriction digestion of PCR products of IL-8 gene in
cases and controls for detection of +781 C/T polymorphism.
Lane 1 – marker (100 bp ladder), Lane 2 – EcoRI digested PCR
product (group I), Lane 3 – EcoRI digested PCR product (group
II), Lane 4 – EcoRI digested PCR product (group III).
Table 2 Distribution of IL-8 genotypes and allele frequencies
in study groups.
Study group CC CT TT C T
Control 18 24 8 0.6 0.4
CAPD 13 25 12 0.51 0.49
CKD 9 21 20 0.39 0.61
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Cytokines are vital modulators of inflammation, and the har-
mony among pro and anti-inflammatory cytokines decides
the incendiary reaction and may intervene the progression of
atherosclerosis and resulting CKD.19,20 Hereditary polymor-
phisms of these cytokines have been appeared to be connected
with comorbidities, for example, cardiovascular sickness, in
ESRD patients21–23, or with ESRD defenselessness24; yet, thereare questionable results that no polymorphisms of the IL6,
IL10, and IL1 genes were connected with ESRD.25 The confir-
mation for polymorphisms in cytokine genes influencing the
risk of CKD itself is rare and this issue has not been com-
pletely illuminated, particularly in the all inclusive
communities.
IL-8 concentration in dialysates from patients with
dynamic Ulcerative colitis was altogether higher than in con-
trols and connected with illness movement.26 The raised
cytokines may assume a part in the protection of the female
urinary tract from certain renal illnesses, for example,
pyelonephritis and other inflammatory and sclerotic kidney
ailments.26 Genotyping patients for IL-8 polymorphisms
might be valuable in anticipating malady result and individual-
izing immunosuppressive treatment.27 Prior studies did not
give obvious proof of the potential commitment of the
hemodialysis strategy to inflammation, as surveyed by markers
of inflammation, for example, cytokine levels and acute phase
protein generation. Diverse examples of pro-inflammatory and
anti-inflammatory cytokine expression and initiation describe
acute kidney injury (AKI), glomerulonephritis (GMN), and
end-stage kidney disease (ESKD). In addition, plasma levels
of specific cytokines and quality polymorphisms for specific
cytokines may have prescient worth in these distinctive clinical
situations.28 Chronic kidney disease (CKD) is connected with
a master provocative state and an overabundance of cardio-
vascular risk. The relationship of single nucleotide polymor-
phisms (SNPs) 251 T/A, +781 C/T, +1633 C/T and
+2767 A/T in the IL-8 quality, +2608 G/C in the CXCR1
quality and +1208 C/T in the CXCR2 quality with weakness
to Intense Polynephritis was reported in the Slovak
population.29
IL-8 – IL-8/CXCL8 was the primary chemoattractant cyto-
kine found, a development in the history of immunology. IL-8/
CXCL8 has a place with the CXC chemokine subfamily and is
a prevalently neutrophil chemoattractant.30,31 The urinary dis-
charge of b2 – microglobulin, IL-6 and IL-8/CXCL8 is con-
nected to renal provocative movement in lupus nephritis.32,33
There is confirmation of expanded urinary discharge of IL-8/
CXCL8 in patients with lupus nephritis or immunoglobulin
An (IgA) nephropathy. Lessening of the urinary levels of IL-
8/CXCL8 has been seen to match with reduction times of
lupus nephritis.34 Then again, Li et al. did not affirm this find-
ing as, disregarding rise of the IL-8/CXCL8 levels in lupus
patients, and no distinction was identified between patients
with and without renal impairment35 Yokoyama et al. exhib-
ited inclusion of IL-8/ CXCL8 in the intense period of IgA
nephropathy, described by endocapillary proliferation.36
Nonetheless, Huang et al. proposed IL-8/CXCL8 cooperation
in the propelled periods of IgA nephropathy, as they demon-
strated expanded urinary levels in correlation with prior phases
of the illness and sound controls.37 Expanded urinary IL-8/
Table 3 Comparison of genotype and allelic frequency distribution in study groups.
Study groups Chi-square value Degree of freedom p-value Odds ratio 95% Confidence interval
Control vs CAPD 1.627 2 <0.05 (0.443) 1.083 0.4945–2.3735
Control vs CKD 8.343 2 <0.05 (0.015) 0.785 0.3562–1.7276
Evaluation of Interleukin 8 gene polymorphism 219CXCL8 was additionally identified at the early phases of dia-
betic nephropathy38. There is additionally clinical and test
proof demonstrating that this chemokine impacts glomerular
permeability38,39. Garin watched that IL-8/CXCL8 organiza-
tion produces proteinuria in creatures, conceivably through
expanded glomerular permeability. Cho et al. recognized
expanded serum and urinary levels of IL-8/CXCL8 in pediatric
patients with backsliding insignificant change nephrotic syn-
drome40. Moreover, Souto et al. demonstrated a positive con-
nection between the urinary discharges of IL-8/CXCL8 and
protein in kids with essential nephrotic syndrome.38 However,
the previous studies fail to interpret IL8 gene polymorphism.
In conclusion, the polymorphism in +781 C/T of IL-8 gene
studied in this work recommends its conceivable part of serv-
ing as an inflammatory marker for chronic kidney disease and
CAPD. The present study has enlisted just a small number of
patients and to affirm our outcomes, larger population study is
exceptionally justified.
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